Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Basilea Pharmaceutica Ltd.

https://www.basilea.com/

Latest From Basilea Pharmaceutica Ltd.

As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023

Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.

US FDA Performance Tracker Drug Review

Basilea Snaps Up Another Antibiotics Program As Pipeline Swells

The company has bagged a preclinical program from struggling Swiss biotech Spexis for $2.3m upfront, its fourth deal in as many months.

Deals Infectious Diseases

Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space

Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.

Executive Changes Leadership

A Year Of Change: Viatris Ploughs Ahead With Brand Ambitions

In 2024, Viatris will initiate the second phase of its long-term business plan, which will see it step away from the perceived volatility of the generics space and begin to move toward innovative and high-growth products. The past year has seen it lay the groundwork for this pivot, shedding surplus business units and making significant hires from the branded space.

Companies Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Basilea Pharmaceutica AG
UsernamePublicRestriction

Register